Intercept Pharmaceuticals Inc (NASDAQ:ICPT)

Tuesday’s trading has closed, but ICPT is being traded in the after-hours session. After-Hours quote »
274.94
Delayed Data
As of 3:59pm ET
 +8.87 / +3.33%
Today’s Change
128.50
Today|||52-Week Range
349.08
+76.24%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$6.4B

Company Description

Intercept Pharmaceuticals, Inc. is a development stage biopharmaceutical company. It focuses on the discovering, developing and commercializing of novel therapeutics to treat chronic liver diseases utilizing its proprietary bile acid chemistry. It develops obeticholic acid, a bile acid analog that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trial to treat portal hypertension; in Phase II clinical trial for the treatment of alcoholic hepatitis; in Phase IIb clinical trial for the treatment of nonalcoholic steatohepatitis; and in Phase IIa clinical trial to treat bile acid diarrhea. Intercept Pharmaceuticals was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.

Contact Information

Intercept Pharmaceuticals, Inc.
450 West 15th Street
New York New York 10011
P:(646) 747-1000
Investor Relations:

Employees

Shareholders

Mutual fund holders53.50%
Individual stakeholders36.83%
Other institutional23.22%

Top Executives

Mark E. PruzanskiPresident, Chief Executive Officer & Director
Barbara Gayle DuncanChief Financial Officer, Secretary & Treasurer
David A. ShapiroChief Medical Officer & EVP-Development
Luciano AdoriniChief Scientific Officer
Rachel L. McMinnChief Strategy Officer

To view my watchlist

Not a member yet?

Sign up now for a free account